Clinical Trials
22 trialsNCT05700448 2026-05-27
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
CStone Pharmaceuticals
Phase 3 Not yet recruiting
NCT07286266 2026-05-27
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT07604766 2026-05-22
RAINFOL-02
Genmab
Phase 3 Not yet recruiting
NCT07578337 2026-05-13
NUMANTIA-2
Nelum Corp
Phase 2 Not yet recruiting
NCT07575191 2026-05-08
Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
Smartwise Sweden AB
Phase 1/2 Not yet recruiting
NCT07570823 2026-05-06
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sinocelltech Ltd.
Phase 3 Not yet recruiting
NCT07564141 2026-05-04
RAINFOLâ„¢-07
Genmab
Phase 3 Not yet recruiting
NCT07488884 2026-04-29
ResQ108B-PANC
ImmunityBio, Inc.
Phase 1 Not yet recruiting
NCT07544056 2026-04-22
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
BeBetter Med Inc
Phase 2/3 Not yet recruiting
NCT07444541 2026-04-16
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Phase 1/2 Not yet recruiting
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT07483554 2026-03-19
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Not yet recruiting
NCT07424287 2026-02-20
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Not yet recruiting
NCT07406542 2026-02-12
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT07383922 2026-02-04
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3 Not yet recruiting
NCT07262567 2025-12-03
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 3 Not yet recruiting
NCT06829823 2025-10-16
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
ImmunityBio, Inc.
Phase 2 Not yet recruiting
NCT07151872 2025-09-03
Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT06892431 2025-03-25
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
NCT06662669 2024-10-29
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1/2 Not yet recruiting
NCT06571461 2024-08-27
Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06446388 2024-06-06
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting